Abstract Rationale: Vitamin K antagonists (VKA), such as warfarin and acenocoumarol, are
widely used for the prevention and treatment of thromboembolic diseases and they are …

Single nucleotide polymorphisms (SNPs) in genes encoding cytochrome P450 enzyme 2C9
(CYP2C9) and Vitamin K epoxide reductase subunit I (VKORC1) make a significant …

Much of the variability in the sensitivity to warfarin in anticoagulated patients is associated
with the c.− 1639G> A polymorphism of the vitaminK‐epoxide reductase (VKORC1) gene …

Coumarin derivatives, including warfarin, acenocoumarol and phenprocoumon, are the
drugs of choice for long-term treatment and prevention of thromboembolic events. The …

Dear Sir, The clinical use of oral anticoagulant therapy is challenging: while an insufficient
dose may increase the risk of thromboembolism, an overdose is associated with an …

The identification of the genes encoding CYP2C9, the principal metabolizing enzyme of the
coumarins, and VKORC1, the molecular target for coumarins, has strongly stimulated the …

Objectives The objective of this study was to determine the quantitative influence of vitamin
K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP 2C9) …

Sažetak Warfarin is the most widely prescribed oral anticoagulant. It shows great (up to 20-
fold) interindividual variability in dose requirement because of both, genetic and …

Polymorphisms in cytochrome P450 (CYP) 2C9 and the vitamin K oxide reductase complex
subunit 1 (VKORC1) greatly affect the maintenance dose of warfarin. To prevent adverse …

The objective of this study was to investigate the influence of genotypes associated with
reduced activity of vitamin K epoxide reductase complex subunit 1 (VKORC1) and …